Zeria Pharmaceutical has patented antibodies targeting TNFa with modified FcRn-binding for improved effector functions and pharmacokinetic properties. The antibody has specific amino acid sequences and affinities to human FcRn at different pH levels, enhancing its therapeutic potential. GlobalData’s report on Zeria Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zeria Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zeria Pharmaceutical's grant share as of May 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies binding to tnfa with modified fcrn-binding
A recently granted patent (Publication Number: US11999781B2) discloses an antibody with a unique combination of properties. The antibody described in the patent comprises a TNFa-binding domain and an FcRn-binding site, exhibiting high affinity to human FcRn at pH 6 with a dissociation equilibrium constant (KD) of less than 100 nM. Interestingly, this antibody shows no or low affinity to human FcRn at pH 7.4, with a KD greater than 10 µM. The specific amino acid sequence of the antibody includes residues 311R, 428E, and 434W, with defined VL and VH domains containing distinct CDR regions.
Moreover, the patent claims highlight additional features of the antibody, such as its exceptional binding affinity to human TNFa with a KD of less than 100 pM. Furthermore, the antibody is specified to be non-fucosylated or have reduced fucosylation, emphasizing its potential therapeutic applications. The patent also extends to cover a pharmaceutical composition comprising this unique antibody along with a pharmaceutically acceptable carrier, indicating the intended use of this novel antibody in therapeutic formulations.
To know more about GlobalData’s detailed insights on Zeria Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
